A Stage 1 trial with ABT-806.
Abbott initiates ABT-806 Phase 1 trial in EGFR expressing tumors Life Technology Pharmaceuticals announced today a milestone linked to monoclonal-antibody 806 licensed to Abbott cyclobenzaprine . A Stage 1 trial with ABT-806, a humanized version of mAb 806 that selectively targets the epidermal growth factor receptor , has been initiated by Abbott in the U.S. The trial will assess the basic safety and pharmacokinetics of ABT-806 in patients with advanced solid tumors likely or known to express EGFR. A clinical research of the chimeric predecessor mAb, ch806, published in PNAS, suggested an ability to focus on and bind selectively to EGFR expressing tumors, with no targeting of normal tissues essentially. (more…)